What Happened
Neurosterix, a clinical-stage biotechnology company spun out of Switzerland's Addex Therapeutics, has closed a $105 million Series B financing, Addex announced on November 11, 2026. The financing came from what Addex described as "a syndicate of leading life science investors." Addex did not identify the individual investors in the round, and did not name a lead investor — a notable omission in an announcement of this size.
Addex did not participate in the financing. Its equity interest in Neurosterix now represents 8.5 percent of the company's issued capital, at a valuation of $18.6 million for that stake.
The proceeds will mainly support the planned Phase 2 clinical development of NTX-253, a highly selective muscarinic M4 positive allosteric modulator (PAM), for schizophrenia. The financing will also support Neurosterix's broader pipeline of selective allosteric modulators for a range of neuropsychiatric disorders. The announcement was carried by GlobeNewswire and reported by Fierce Biotech and Dealroom.
Neurosterix was launched by Addex in April 2024 with a $65 million Series A led by funds affiliated with Perceptive Advisors, the life sciences investment firm. Neurosterix is led by CEO Fred Callori, who is also a managing director at Perceptive. The Series B is substantially larger than the launch round that created the company.
What the Company Does
Neurosterix is a clinical-stage biotechnology company focused on transforming neuropsychiatric care through selective allosteric modulation — a mouthful that describes a precise way of tuning the brain's signaling systems.
To understand the approach, it helps to start with the disease. Schizophrenia affects roughly 24 million people worldwide, according to the World Health Organization, and its symptoms — hallucinations, delusions, disorganized thinking, and a loss of motivation and social function — are among the most disabling in medicine. Existing antipsychotic drugs, which mostly work by blocking dopamine receptors, help many patients but carry serious side effects, including movement disorders, weight gain, and metabolic problems. Many patients stop taking them.
NTX-253 takes a different route. It targets the muscarinic M4 receptor, a protein on the surface of brain cells that helps regulate the release of acetylcholine, a neurotransmitter involved in cognition and perception. Rather than switching the receptor fully on or off, NTX-253 is a positive allosteric modulator: it binds to a secondary site on the receptor and amplifies the receptor's natural response. The idea is to get a more precise, gentler effect — easing psychosis symptoms without the movement disorders tied to older antipsychotics.
The approach gained credibility in 2024, when Bristol Myers Squibb's Cobenfy became the first muscarinic-targeting antipsychotic approved for schizophrenia. Dealroom reported that Neurosterix has recruited several figures involved in Cobenfy's development.
NTX-253 has completed Phase 1 studies, which test safety in healthy volunteers, and is now being steered toward Phase 2, which will test whether the drug actually works in patients with schizophrenia. That is the critical test: Phase 1 shows a drug is safe enough to try, but Phase 2 is where a drug either demonstrates efficacy or fails.
Why It Matters
Schizophrenia is one of the largest unmet needs in medicine, and a new mechanism of action is a rare event. For decades, nearly every approved antipsychotic has worked through the same dopamine-blocking pathway, and the side effects of that pathway are a major reason patients abandon treatment. A drug that works through muscarinic receptors, with a different side-effect profile, could help patients who cannot tolerate existing treatments — and the market for such a drug is very large.
The $105 million round is also a sign of how the muscarinic field has changed since Cobenfy's approval. What was once a speculative idea is now a validated mechanism with a commercial precedent, and investors are willing to fund follow-on companies that aim to improve on it.
The financing structure carries its own story. Addex, the parent company, did not participate in the round and saw its stake diluted to 8.5 percent. That is the normal fate of a spin-out: the parent contributes the science and takes a minority stake, while new investors fund the expensive clinical work.
The risks are substantial and should not be understated. NTX-253 has not yet shown that it works in patients, and most drugs that enter Phase 2 fail.
What This Means for Founders and Investors
For founders in biotech, Neurosterix illustrates the spin-out model at its best: a parent company with a research platform and a promising asset, a specialist investor willing to fund the new company's launch, and a mechanism that gained validation from a competitor's success. The lesson is that timing matters as much as science — Neurosterix's Series B landed after Cobenfy proved the muscarinic mechanism could reach the market, which made the investment case far easier to make.
For investors, the round is a reminder of both the upside and the risk in neuropsychiatry. A successful schizophrenia drug can generate billions in revenue, and the unmet need is enormous. But the path runs through Phase 2 and Phase 3 trials that take years and can fail at any stage. The unnamed syndicate behind this round is betting that selectivity and the Cobenfy precedent tilt the odds in Neurosterix's favor. The Phase 2 results, when they come, will be the verdict.
Angeled.com connects founders with investors.
Fierce Biotech
Dealroom
Read Next
General Translation Raises $27 Million Series A Led by a16z to Build Agent-First Localization Infrastructure
LangChain Raises $300 Million Led by CapitalG at a $3 Billion Valuation to Build the Agent Stack
Mount Thor Raises $45 Million to Run Cloud Fleets of Macs for AI Agents
OpenAI Reportedly Raises $15 Billion at a $1.25 Trillion Valuation
Q-CTRL Raises $290 Million Series C Led by Salesforce Ventures, Reaching Unicorn Status
SE3 Raises $30 Million Series A Led by Accel



